Dorsey & Whitney Trust CO LLC Buys 3,984 Shares of Haleon plc (NYSE:HLN)

Dorsey & Whitney Trust CO LLC raised its stake in Haleon plc (NYSE:HLN) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 31,027 shares of the company’s stock after purchasing an additional 3,984 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Haleon were worth $296,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Sierra Ocean LLC bought a new position in shares of Haleon in the 4th quarter worth $26,000. Versant Capital Management Inc increased its holdings in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Haleon in the 4th quarter worth $35,000. Toronto Dominion Bank increased its holdings in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management bought a new position in shares of Haleon in the 4th quarter worth $39,000. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.7 %

Shares of HLN opened at $10.38 on Tuesday. The stock has a market capitalization of $46.97 billion, a P/E ratio of 30.51, a PEG ratio of 2.82 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $9.68 and a two-hundred day simple moving average of $9.86. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, research analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a $0.1166 dividend. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HLN. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.